Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies

Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies

Craig LaForce,1 Eric Derom,2 Ulrich Bothner,3 Isabel M Kloer,3 Matthias Trampisch,4 Roland Buhl5 1NC Clinical Research, Raleigh, NC, USA; 2Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; 3Pharmacovigilance, Boehringer Ingelheim International GmbH, Ingelheim, Germany;...

Full description

Bibliographic Details
Main Authors: LaForce C, Derom E, Bothner U, Kloer IM, Trampisch M, Buhl R
Format: Article
Language:English
Published: Dove Medical Press 2018-06-01
Series:International Journal of COPD
Subjects:
COPD
renal impairment
comorbidities
tiotropium
olodaterol
safety
Online Access:https://www.dovepress.com/long-term-safety-of-tiotropiumolodaterol-respimatreg-in-patients-with--peer-reviewed-article-COPD

Internet

https://www.dovepress.com/long-term-safety-of-tiotropiumolodaterol-respimatreg-in-patients-with--peer-reviewed-article-COPD

Similar Items